Subscribe to Newsletter

Business Practice

Business & Regulation Business Practice

Calling Out Misleading Information

| Rob Coker | 2 min read

FDA letter sent to Edenbridge Pharmaceuticals demonstrates the challenges of getting pharma advertising right.

Manufacture Contract Development Services

Resilient Supply Chains in an Uncertain World; View From a CDMO

| 3 min read

From geopolitical conflicts to cyber threats, CDMOs must rethink resilience.

Business & Regulation Business Practice

Biden’s Legacy; Trump’s Agenda: Part 2

| 7 min read

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

Business & Regulation Business Practice

Biden’s Legacy; Trump’s Agenda: Part 1

| 10 min read

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

Manufacture Advanced Medicine

The Risks and Rewards of Rare Diseases

| Stephanie Vine | 4 min read

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.

Business & Regulation Business Practice

Where Does All the Profit Go?

| Stephanie Vine | 2 min read

To shareholders – according to an analysis of financial reports from healthcare companies.

Business & Regulation Business Practice

GenAI: Automating Regulatory Submissions

| Agnes Cwienczek | 4 min read

Within two years, pharma companies may be able to rely on technology to automatically create and cross-check entire regulatory submissions.

Business & Regulation Contract Manufacturing Services

The Secret to Being a Good Employer

| 4 min read

Why you shouldn’t neglect the importance of blending people, culture, and strategy to foster success in a business.

Business & Regulation Business Practice

Pharma’s Dealmaking January

| 3 min read

Here’s a roundup of ten of the most eye-catching deals so far in 2025.

Business & Regulation Standards & Regulation

Panic in US Science

| Stephanie Vine | 3 min read

The Trump administration’s move to pause federal funding while projects are vetted causes concern and lawsuits

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register